COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

November 15, 2022

Conditions

SARS-CoV-2 InfectionCoronavirus Disease 2019 (COVID-19)

Interventions

BIOLOGICAL

SARS-CoV-2 mRNA Vaccine (CVnCoV)

Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.

BIOLOGICAL

Quadrivalent influenza vaccine (QIV)

One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.

OTHER

Placebo

One intramuscular injection as normal saline \[0.9% NaCl\].